Effect of Bryophyllum pinnatum versus fenoterol on uterine contractility by Gwehenberger, B et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2004
Effect of Bryophyllum pinnatum versus fenoterol on uterine
contractility
Gwehenberger, B; Rist, L; Huch, R; von Mandach, U
Gwehenberger, B; Rist, L; Huch, R; von Mandach, U (2004). Effect of Bryophyllum pinnatum versus fenoterol on
uterine contractility. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology,
113(2):164-171.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
European Journal of Obstetrics &amp; Gynecology and Reproductive Biology 2004, 113(2):164-171.
Gwehenberger, B; Rist, L; Huch, R; von Mandach, U (2004). Effect of Bryophyllum pinnatum versus fenoterol on
uterine contractility. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology,
113(2):164-171.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
European Journal of Obstetrics &amp; Gynecology and Reproductive Biology 2004, 113(2):164-171.
Effect of Bryophyllum pinnatum versus fenoterol on uterine
contractility
Abstract
To characterise the phytotherapeutic tocolytic Bryophyllum pinnatum in vitro versus the conventional
betamimetic, fenoterol, in human myometrium. STUDY DESIGN: Contractility (endpoints: area under
the curve (AUC), amplitude and frequency of isometric force development) was measured in strips of
term myometrium biopsied at caesarean section in 14 women and exposed to increasing concentrations
of B. pinnatum versus +/- oxytocin 1 U/l. RESULTS: Inhibition of spontaneous contraction by B.
pinnatum was concentration-dependent: 16% at maximum concentration (10(4) mg/l), or 53% that with
fenoterol 5 x 10(-8)mol/l. B. pinnatum increased contraction frequency by 91% at constant amplitude
and inhibited oxytocin-stimulated contractions by 20% (AUC) at constant amplitude with slightly
decreased frequency. Fenoterol decreased contraction AUC by 50% with a significant decrease in
frequency. CONCLUSION: Our in vitro data confirm the tocolytic activity of B. pinnatum observed in
alternative medicine centres and may justify further clinical studies. 
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Abstract
Objective: To characterise the phytotherapeutic tocolytic Bryophyllum pinnatum in vitro versus the conventional betamimetic,
fenoterol, in human myometrium. Study design: Contractility (endpoints: area under the curve (AUC), amplitude and frequency of
isometric force development) was measured in strips of term myometrium biopsied at caesarean section in 14 women and exposed to
increasing concentrations of B. pinnatum versus fenoterol oxytocin 1 U/l. Results: Inhibition of spontaneous contraction by B. pinnatum
was concentration-dependent: 16% at maximum concentration (104 mg/l), or 53% that with fenoterol 5 108 mol/l. B. pinnatum
increased contraction frequency by 91% at constant amplitude and inhibited oxytocin-stimulated contractions by 20% (AUC) at constant
amplitude with slightly decreased frequency. Fenoterol decreased contraction AUC by 50% with a significant decrease in frequency.
Conclusion: Our in vitro data confirm the tocolytic activity of B. pinnatum observed in alternative medicine centres and may justify further
clinical studies.
# 2003 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Although Bryophyllum pinnatum (Lam.) (synonym:
Kalanchoe pinnata, Lam.; common names: life plant, air
plant [Mexican], love plant, Canterbury bells, cathedral
bells) is widely used in the folk medicine of its indigenous
regions (Madagascar, tropical Africa, India, China, Austra-
lia, Hawaii and tropical America [1,2]), it remains relatively
little researched. The name Bryophyllum comes from bruo
‘I sprout’ and jullon ‘leaf’: the plant, classified as a weed,
is notorious for its growth potential. Shortly after a leaf falls
to the ground, a whole garland of new little plants develops
from the notches along the leaf margin. Studies have shown
the following in vitro effects in rodent tissue: positive
inotropism, sedation, H1 antagonism (ileum, bronchial mus-
cle, peripheral vasculature), and antimicrobial activity [3–
5]. Identified active ingredients include bufadienolides,
flavonoids, glycosides, steroids and organic acids [6–10].
B. pinnatum has been used since 1921, mainly as a
sedative, by psychiatrists in alternative medicine and was
first introduced in 1970 at a German complementary/alter-
native medicine (CAM) centre, the Herdecke Community
Hospital, as a treatment for premature labour [11,12]. A 5%
preparation was administered parenterally at a dose of
580 mg/h until contractions ceased, after which it was
administered as a 50% slurry at a dose of 200 mg/h, sup-
plemented by fenoterol 120 mg/h if insufficiently effective
alone. Clinical outcome and inhibition of labour were
similar to those on fenoterol [11,12]. However, in contrast
to the well-documented side effects of conventional labour
inhibitors, especially of the cardio vascular system, which
can be serious for both for mother and baby, no adverse signs
or symptoms are known until now. B. pinnatum 5% is also
used as a 10 ml i.v. bolus during delivery if contractions are
too strong, frequent or painful; the effect, which is rapidly
visible on the cardiotocogram, is much less a matter of direct
inhibition than of inducing more rhythmic contractions [11].
The purpose of the present study was to examine the effect of
B. pinnatum on the contractility of human myometrium in
vitro as a preliminary approach to evaluating its use in
clinical practice.
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2. Materials and methods
2.1. Design
The study was approved by our institutional ethics com-
mittee. Before tissue removal each woman confirmed in
writing that she had been fully informed about the purpose of
the study and that she consented to the procedure. An 0.5–
3 g myometrial biopsy was taken from each volunteer at
term during elective or non-elective caesarean section. The
inclusion criteria were elective and non-elective caesarean
section; the exclusion criteria were prior tocolytic therapy,
intra-amniotic or any other infection, and preeclampsia.
2.2. Procedure
After delivering the child and placenta and securing hae-
mostasis, an approximate 2 cm 0:5 cm 0:5 cm strip of
myometrium was taken from the superior edge of the hyster-
otomy incision, placed immediately in iced Ringer or mod-
ified Krebs solution (NaCl 118; KCl 4.7; CaCl2 2.48; KH2PO4
1.24; MgSO4 1.21; NaHCO3 24.9; glucose 10.0; EDTA
0.034 mmol/l), and transported immediately to the laboratory
for processing. Approximate 2 10 mm longitudinal strips
of muscle fibre were prepared as delicately as possible, then
immediately clamped vertically in the experimental apparatus
and immersed in the organ bath filled with Krebs solution
maintained at 37 8C and gassed (95% O2, 5% CO2, pH 7.4).
Immediately after immersion, a 2 g load was applied to the
strips, causing initial relaxation or twitching. Experimental
data were not recorded until at least five regular contractions
were obtained. Strips which did not contract regularly were
not included in the study. We recorded the number of spon-
taneously contracting strips per patient.
2.3. Apparatus
The apparatus consisted of a jacketed organ bath with
water and gas feed lines. Each myometrial strip was clamped
at one end, while the other end was fixed to a clamp
connected to the force transducer via a thin plastic thread.
The force transducer (max green and red, output black and
white 350 O, 60 g, 12 mm, input 7.5 V, Scaime France-
74105 Annemasse) recorded the contractions of the muscle
strips isometrically. An amplifier (MT8P, Lectromed, Letch-
worth SG6 1HT, UK) dispatched the starting signals to an
electronic recorder (408 WþW electronic).
2.4. Analytical procedure
2.4.1. Test compounds
 B. pinnatum: Bryophyllum stock solution (100%), and 5%
solution for injection (10 ml ampoules), Weleda AG,
Arlesheim, Switzerland.
 Fenoterol: Partusisten1 ampoules (0.5 mg/10 ml), Boeh-
ringer Ingelheim, Germany.
 Oxytocin: Syntocinon1 ampoules (5 IU/ml), Novartis
Pharma, Basel, Switzerland.
2.4.2. Dose-finding study
 B. pinnatum: Various amounts of Bryophyllum stock
solution (100%) were added to the organ bath to establish
an approximate range of myometrial tolerability.
 Fenoterol: Based on the range of plasma levels with
physiological activity (225–6000 ng/l, equivalent to
6:5 1010 to 1:6 108 mol/l) [13], fenoterol was used
at concentrations between 1010 and 5 108 mol/l.
2.4.3. Experiment 1: Effect of B. pinnatum or fenoterol
on spontaneous contractions
After obtaining good spontaneous activity in Krebs solu-
tion (baseline), B. pinnatum or fenoterol was added at
increasing concentrations (test). The timing of each addition
was standardised to take place during the post-contraction
relaxation phase. Before each addition the volume to be
added was removed from the organ bath. An otherwise
identically treated muscle strip with no added test substance
(i.e. Krebs solution only) was run in parallel over each entire
experiment as a control.
2.4.4. Experiment 2: Effect of B. pinnatum or fenoterol
on oxytocin-stimulated contractions
Oxytocin (Syntocinon1 1 IU/l) triggered a contraction
whose area under the curve (AUC) over 10 min served as
the baseline value [14]. Over the following 1 h the Krebs
solution was replaced every 10 min to wash out the oxytocin.
B. pinnatum or fenoterol followed by oxytocin 1 U/l were then
added (test). Anotherwise identically treatedmuscle stripwith
only 1 IU/l oxytocin inKrebssolution (theoxytocin was added
for both the baseline and test values) was run as the control.
2.5. Data processing
Contractility endpoints were AUC, amplitude and fre-
quency. The curves were scanned from thermal paper and
processed in Adobe Photoshop 5.0. AUC values were cal-
culated using the Windows version of the NIH Image
program (Scion Image Beta 4.02 Win; US National Institute
of Health: http://www.rsb.info.nih.gov/nih-image/). The
amplitude of each contraction was measured from baseline
to peak (by hand to the nearest 0.25 mm). Frequency was
calculated from the time (in seconds) required for the
respective number of contractions (usually 2–3). Since this
yielded very low values, it was multiplied by 1000 to give
the number of contractions/1000 s.
Spontaneous contractions: the mean of the five contrac-
tions in Krebs solution before any administration of test
substance was defined as 0 (baseline) and the corresponding
AUC was defined as 100% spontaneous contractile activity;
the mean of the subsequent two contractions was used as
the test value for the respective concentration of B. pinnatum
or fenoterol. Oxytocin-stimulated contractions: the first
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post-oxytocin contraction in Krebs solution over the 10 min
period was defined as the (Krebsþ oxytocin) baseline; the
test value for the respective concentration of B. pinnatum or
fenoterol was defined as the mean contractions occurring in
the 10 min post-substance administration period (B. pinna-
tum or fenoterol followed by 1 IU/l oxytocin).
2.6. Statistical methods
The statistical analysis was performed in Stat View 4þ.
Mean AUC, amplitude and frequency (absolute contractility
endpoints) were calculated from the data obtained at each
concentration with the standard error and median. The
relative contractility endpoint was the fraction (%) of the
mean AUC value in Krebs solution before test substance
addition (baseline ¼ 100%).
3. Results
3.1. Population
Muscle samples were taken from a total of 18 donors. Those
from subjects 1, 5, 10 and 13 were excluded due to absence of
spontaneous contraction, leaving a total of 14 donors, the
majority of whom (n ¼ 12) underwent elective section. In
eight patients it was the first section, in five their second
section, and in one her third section; the six repeat sections
formed 43% of the total (Table 1). Patients undergoing
elective section received local (peridural) anaesthesia; those
undergoing non-elective section received general anaesthesia.
3.2. Spontaneous contractility without test
substance administration
Each donor muscle biopsy yielded an average of six
strips. Of the original total 85 strips from the 14 donors,
54 (64%) were included in the final analysis. Of the 50 strips
from first-section donors (n ¼ 8), 33 (66%) displayed on
average good spontaneous contractions; without the one
non-elective section with very poor contractility (2
strips ¼ 29%, due to arrested labour and prior oxytocin
induction), the success rate would have been 72%. The
corresponding value for samples from repeat (x  2) sec-
tions was 60%.
3.3. Dose/effect study: B. pinnatum
Spontaneous contraction: After the addition of Bryophyl-
lum stock solution (final organ bath concentration: 20% ¼
2 105 mg/l), a contraction of rather smaller amplitude
occurred followed by incomplete relaxation. After
60 min, no further contractions could be triggered even after
washout and with oxytocin (Fig. 1). B. pinnatum 105 mg/l
gave a similar result. Concentrations <105 mg/l were there-
fore used in subsequent studies.
Oxytocin-stimulated contractions: The lowest relaxant
concentration of B. pinnatum was 5 101 mg/l.
3.4. Effect on spontaneous contractions
3.4.1. B. pinnatum
Experiment 1 yielded the following results (Table 2):
 A relaxant effect, as shown by a concentration-dependent
reduction in AUC (to 16% of baseline at 104 mg/l,
P < 0:01) (Fig. 2a); the control muscle strips in Krebs
solution displayed no major changes throughout the
experiment (contractions 5–25) (Fig. 3a).
 Amplitudes virtually unchanged from the pre-administra-
tion baseline.
 A concentration-dependent increase in frequency (up to
90% more at a concentration of 104 mg/l).
3.4.2. Fenoterol
 A relaxant effect, shown by a concentration-dependent
reduction in AUC; reduction was maximal 30% at a
concentration of 5 108 mol/l (P < 0:05 versus base-
line) (Fig. 2b).
 A slight, concentration-dependent decrease in amplitude
(17% decrease at a concentration of 5 108 mol/l,
P < 0:05 versus baseline).
 The frequencies showed two minima, falling by 9% at a
concentration of 5 1010 mol/l, then increasing again to
99%, with a second minimum of 79% (21% decrease) at a
concentration of 5 108 mol/l (NS).
3.5. Effect on oxytocin-stimulated contractions
3.5.1. B. pinnatum
Experiment 2 gave the following results after the admin-
istration of B. pinnatum with oxytocin 1 U/l in a concentra-
tion range of 5 101 to 104 mg/l:
Table 1
Patient data
Patient Indication Section
(E/NEa, no.)
Gestational age
(completed weeks)
2 Patient request E, 1 37
3 Cephalopelvic disproportion E, 2 38
4 Mucoviscidosis E, 1 34
6 Cephalopelvic disproportion E, 2 40
7 Breech presentation NE, 1 38
8 Third caesarean section E, 3 38
9 Cephalopelvic disproportion E, 2 38
11 Diabetes mellitus E, 1 38
12 Breech presentation E, 1 38
14 Arrested labour NE, 2 40
15 Fetal malformation E, 1 37
16 Previous vacuum extraction E, 1 38
17 Cephalopelvic disproportion E, 2 38
18 Patient request E, 1 40
Patients 1, 5, 10 and 13 were excluded.
a Elective/non-elective.
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 A concentration-dependent reduction in AUC of just under
10% with B. pinnatum 5 101 mg/l and of just under 20%
with B. pinnatum 104 mg/l (Fig. 3a). The mean reduction
over the entire test concentration range was 15% (P < 0:05
versus the oxytocin/Krebs baseline). The control oxytocin/
Krebs strips displayed no significant change.
 Unchanged amplitudes at 5 101 mg/l and an 8%
decrease in mean amplitude at 104 mg/l.
 A 33% decrease in frequency with B. pinnatum
5 103 mg/l (Fig. 4a).
3.5.2. Fenoterol
 At a concentration of 5 109 mol/l, fenoterol decreased
AUC by a mean 23%, and by 50% at the higher con-
centration of 107 mol/l (Fig. 3b). The mean relaxant
effect of the test concentration range was a 39% reduction
in AUC (P < 0:05 versus the oxytocin/Krebs baseline).
 The mean decrease in amplitude after fenoterol
5 109 mol/l was just under 30%; after fenoterol
107 mol/l, it was 7%.
 The mean decrease in frequency was 30% after fenoterol
with oxytocin at both concentration ranges (P < 0:05
versus oxytocin/Krebs baseline) (Fig. 4b).
4. Comment
This is the first study showing the relaxant effect in vitro
of B. pinnatum on the contractility of human myometrium
and reinforcing therefore it’s tocolytic activity observed in
alternative medicine centres.
Fig. 1. Effect of B. pinnatum 2 105 mg/ml on muscle strip contractility.
Table 2
Area under the curve (AUC), amplitude and frequency of muscle strip contractility in response to increasing concentrations of B. pinnatum and fenoterol
Concentration AUC (cm2) Baseline (%)a Amplitude (mm) Frequency (s1) (103)
Mean S:E: (median) Mean S:E: (median) Mean S:E: (median)
Bryophyllum pinnatum (n ¼ 12) (mg/ml)
0b 0.95  0.19 (0.87) 100 26.15  3.99 (27.30) 2.09  0.37 (1.82)
102 0.94  0.19 (0.88) 99 27.23  4.41 (28.13) 2.28  0.49 (1.78)
5  102 0.88  0.18 (0.80) 93 27.04  4.46 (27.75) 2.19  0.37 (1.84)
103 0.89  0.17 (0.81) 94 27.39  4.30 (28.19)* 2.18  0.34 (1.85)
5  103 0.81  0.16 (0.74)** 85 26.99  4.42 (28.69) 2.93  0.51 (2.53)***
104 0.80  0.16 (0.67)** 84 26.92  4.26 (29.70) 3.99  0.94 (3.12)***
Fenoterol (n ¼ 7) (mol/l)
0b 0.79  0.24 (0.77) 100 23.43  5.74 (23.10) 2.80  0.71 (2.02)
1010 0.77  0.25 (0.74) 97 23.73  5.82 (24.88) 2.87  0.71 (2.41)
5  1010 0.75  0.24 (0.66) 95 23.96  5.81(25.50) 2.56  0.61 (2.03)
109 0.75  0.25 (0.66) 95 23.62  6.00 (26.00) 2.76  0.64 (2.25)
5  109 0.70  0.23 (0.63)* 89 23.11  6.13 (25.50) 2.64  0.56 (2.46)
108 0.66  0.21 (0.62)* 84 22.31  6.15 (24.88) 2.53  0.57 (2.17)
5  108c 0.63  0.21 (0.55)* 70 22.18  5.68 (24.00)* 2.30  0.69 (1.86)
a Krebs solution only.
b Baseline: Krebs solution before adding test substance.
c Only six myometrial strips (baseline AUC: 0:90 0:26 (0.98); amplitude: 26:78 5:51 (26.03); frequency: 2:91 0:83 (2.01)).
* P < 0:05 vs. baseline.
** P < 0:01 vs. baseline.
*** P < 0:005 vs. baseline.
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4.1. Tissue
The success rate—64% of well-contracting muscle
strips—was acceptable considering the high proportion of
repeat sections (43%) and the decreased contractility result-
ing from the higher proportion of connective tissue neigh-
bouring old hysterotomy scars. David et al. [14] reckoned on
a 75% success rate with 10% repeat sections.
4.2. Concentration range of B. pinnatum and toxicity
In the absence of pharmacokinetic data on B. pinnatum,
we were forced to rely on the doses in clinical use to
determine the concentration range. The test preparation of
B. pinnatum was based on an aqueous fresh leaf extract
obtained as directed by the German Homeopathic Pharma-
copoeia (HAB). This can be termed the 100% solution in
that all the preparations were diluted from it. Treatment is
usually administered parenterally at a dosage of 580 mg/h
(5 104 mg/(l h)) using 5% ampoules (Weleda, CH-4144
Arlesheim). As soon as contractions cease, treatment is
switched to a dosage of 200 mg/h using a 50% oral solution.
On this basis, we established the range of concentrations that
were minimally to maximally active in vitro (compatible
with a reversible myometrial response) in the preliminary
dose-finding experiments and only used concentrations
<104 mg/l in the further experiments.
The most feared components of Bryophyllum prepara-
tions are the bufadienolides, which have cardiac glycoside
activity and are notorious in veterinary medicine for caus-
ing fatal cardiotoxicity in calves. Veterinary toxicity
occurred after the ingestion of large amounts of the very
fresh plant [16,17]. To date no side effects have been
reported at the dosages in clinical use [11,12,15]. In fact,
analysis of the test preparation (100% aqueous leaf extract)
by the manufacturer, Weleda, detected no bufadienolides.
This result is confirmed by other sources indicating that
bufadienolides are present in aqueous solution at much
lower levels than in fresh roots or a non-aqueous extract
[4,18].
We should also bear in mind that the activity of phyto-
pharmaceuticals in vivo reflects the interactions between
their multiple constituents [19]. However, this aspect is not
necessarily reflected in vitro.
4.3. Spontaneous contractions
B. pinnatum displayed concentration-dependent inhibi-
tion of spontaneous contractility. The maximum reduction in
AUC was 16%. Ba´ra´ny and Ba´ra´ny [20] also observed an
increase in frequency associated with the decrease in AUC
after adding isoproterenol and 3-isobutyl-l-methylxanthine
to carbachol-stimulated myometrial contractions in estro-
gen-stimulated rats. Despite the increase in frequency they
found an overall inhibition of contractility. It thus follows
that the individual parameters of amplitude and frequency
cannot be evaluated in isolation, since in calculating the
AUC the increase or decrease in the basal tone of the
contraction curve is a major factor. B. pinnatum is at least
half as active as fenoterol, which exerts maximum inhibition
(30%) at a concentration of 5 108 mol/l.
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Fig. 2. (a) Mean area under the curve (AUC) of muscle strip contractility
(n ¼ 12) in response to increasing concentrations of B. pinnatum.
P < 0:01 vs. Krebs solution without B. pinnatum. (b) Mean area under
the curve (AUC) of muscle strip contractility (n ¼ 7) in response to
increasing concentrations of fenoterol. P < 0:05 vs. Krebs solution
without fenoterol. (c) Mean area under the curve (AUC) of muscle strip
contractility (n ¼ 5) in Krebs solution, showing no significant changes
from contraction 5 to 25.
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A further possible explanation for the effect of B. pinna-
tum on spontaneous contractions is its antihistamine activity.
Animal studies by Nassis et al. [21] revealed an H1-receptor
antagonist in the pressed juice of B. pinnatum. In vitro
studies by Bergant et al. [22] with human myometrium
showed that the biogenic amine, histamine, augments uter-
ine activity. Martinez-Mir et al. [23] also showed inhibition
of histamine-induced contraction in vitro by the H1-receptor
antagonist clemizole, contrasting with augmentation by the
H2-receptor antagonist, ranitidine, leading them to the con-
clusion that myometrium contained both H1 and H2 recep-
tors, with contraction-inhibiting and promoting properties,
respectively.
Since B. pinnatum has also been postulated to have anti-
inflammatory activity [11], it may also inhibit prostaglandin
synthesis. Prostaglandin E2, in particular, by potentiating the
effect of oxytocin, plays an important role in the initiation of
contractions [24].
4.4. Oxytocin-stimulated contraction
B. pinnatum had a relaxant effect on oxytocin-stimulated
contraction at a minimum concentration almost 100-fold
lower than in the case of spontaneous contraction (10%
reduction in AUC even at 5 101 mg/l, and 20% at
104 mg/l). The maximum reduction in AUC with fenoterol
(just under 50%) exceeded published values: at a similar
concentration range David et al. [14] found a maximum
reduction of 21%, and Bauer et al. [25] a maximum of 36%.
B. pinnatum 104 mg/l decreased amplitude by 8% versus a
maximum decrease of 30% with fenoterol 5 109 mol/l.
After its initial administration to determine the baseline
value, oxytocin had to be washed out, thus delaying admin-
istration of the test agents. Since the structures mediating the
mode of action of B. pinnatum remain unidentified and we
do not know whether receptors with a short half-life are
involved, the duration of future experiments should be
limited. The repeated changes of Krebs solution in the organ
bath required by the washout process are also a substantial
cause of irritation to the contracting muscle strips.
Premature labour is attributed to many different maternal
and fetal risk factors and tocolysis is one of possible
managements. We must recall that tocolysis is a sympto-
matic therapy and that even different members of the same
tocolytic class display wide variation in their ability to
inhibit contraction in vivo (premature labour in particular).
Fig. 3. (a) Mean area under the curve (AUC) of muscle strip contractility (n ¼ 13) in response to B. pinnatum (*) 5 101 mg/l, ( ) 5 103 mg/l, and (*)
104 mg/l followed by oxytocin 1 U/l. P < 0:05 overall B. pinnatum vs. Krebs solution without B. pinnatum. No significant changes in Krebsþ oxytocin 1 U/l
((!) control). (b) Mean area under the curve (AUC) of muscle strip contractility (n ¼ 7) in response to fenoterol ( ) 5 109 mol/l and (&) 107 mol/l
followed by oxytocin 1 U/l. P < 0:05 overall fenoterol vs. Krebs solution without fenoterol. No significant changes in Krebsþ oxytocin 1 U/l ((!) control).
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Nor do in vitro studies always provide a reliable guide to
clinical activity. Thus, the betamimetic fenoterol, a standard
clinical tocolytic, does not totally inhibit spontaneous con-
traction in vitro, but simply modifies the contraction pattern.
The promising clinical efficacy of B. pinnatum is what
prompted us to investigated its effect on uterine contractility
in vitro. Our results show inhibition of contraction, combined
with a change in contraction pattern. Spontaneous contraction
decreases in amplitude while increasing in frequency, corre-
sponding to the increased rhythmicity of labour often
observed clinically in response to B. pinnatum; in the case
of oxytocin-stimulated contraction, frequency decreases too.
On this basis, we believe that clinical use of B. pinnatum is
entirely legitimate, whether as monotherapy or in combina-
tion with synthetic tocolytics, depending on the intensity of
labour. However, dose and effect still require more detailed
characterisation in prospective clinical studies.
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